Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9232217 | 1.00 | MAPT (0.53) | MAPTRAPGEF4LMNAALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL1426197 | 0.98 | MAPT (0.52) | MAPTRAPGEF4LMNAALDH1A1HPGD | |
| SCHEMBL9801566 | 0.82 | MAPT (0.46) | MAPTRAPGEF4ALDH1A1HPGDUSP2 | |
| SCHEMBL27553541 | 0.81 | MAPT (0.53) | MAPTRAPGEF4LMNAALDH1A1HPGD | |
| SCHEMBL1143322 | 0.79 | LMNA (0.59) | MAPTRAPGEF4LMNAALDH1A1HPGD | |
| SCHEMBL11412016 | 0.79 | MAPT (0.56) | MAPTRAPGEF4LMNAALDH1A1HPGD | |
| SCHEMBL29661766 | 0.78 | MEN1 (0.50) | MAPTLMNAALDH1A1HPGDMEN1 | |
| SCHEMBL5914549 | 0.78 | MEN1 (0.50) | MAPTLMNAALDH1A1HPGDMEN1 | |
| Hydrochloric Acid SCHEMBL671039 | 0.77 | LMNA (0.58) | MAPTRAPGEF4LMNAALDH1A1HPGD | |
| SCHEMBL100946 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608816-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Monte Rosa Therapeutics AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-21 | — | — | US | disclosed |
| CN-120081802-A | Heterocyclic substituted benzamide derivative and application thereof | 南华大学附属第一医院 | 2025-06-03 | — | — | CN | disclosed |
| CN-118804911-A | Acrylamide compound | NRG治疗有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024092039-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| CN-116096705-A | Novel compounds | NRG治疗有限公司 | 2023-05-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | MAPT 3248/4885RAPGEF4 2233/4885LMNA 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.